MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap. Investor Call Details: Date and Time: June 11, 2024, 4:30pm ET. Register Toda ...